The fifth edition of the European Society for Medical Congress (ESMO) Asia Congress took place from 22 to 24 November 2019 at the Suntec Singapore Convention & Exhibition Centre where experienced international experts gathered to present a comprehensive, regional approach to multi-disciplinary oncology.

The GH AMEA team was in full force at our ESMO booth, engaging medical oncologists from the region and sharing with them about our flagship product, Guardant360® assay. ESMO Asia aims to tackle the most burning issues of prevalent cancer types in the region, educating conference attendees through a high-quality programme designed to share standards of care for the benefit of cancer patients.

Three abstracts from GH AMEA were also accepted as poster presentations by ESMO Asia Congress.

1. Circulating Tumor DNA (ctDNA) Identifies Actionable Genetic Alterations in Middle Eastern and Asian (MEA) Patients Diagnosed with Carcinoma of Unknown Primary (CUP)
   Authors: Nir Peled, Hitomi Okuma, Ofer Rotem, Elizabeth Dudnik, Sada Ikeda, Salomon Stemmer, Steven Olsen
2. Prevalence of Uncommon Epidermal Growth Factor Receptor (EGFR) Alterations Detected by Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer (NSCLC) Patients in Hong Kong
   Authors: Oscar Siu-Hong Chan, Gordon Cheung, Michelle Mei Lin Lee, Steven Olsen
3. Real World Prospective Clinical Impact of Finding Actionable Genomic Alterations by Plasma Cell-Free DNA Next Generation Sequencing in Advanced Non-Small Cell Lung Cancer.
   Authors: Beung-Chul Ahn, Seoyoung Lee, You Jin Chun, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho